Critical Illness / AXA Mandiri
Asuransi Tambahan Mandiri Critical Care
★ The Insurer’s Play
analytical interpretationLimited read — analysis pending. Likely intent: sell lump-sum protection against a small set of high-cost diagnoses. Full read pending a Strategic Brief.
Our read of the insurer’s design intent — not their stated words. Use it to judge fit, not as a fact about the policy.
Who this fits — and who it doesn’t
Fit guidance becomes available once this product has a Strategic Brief.
Expert · technical detail
How Critical Illness products differ
Still building · 77% coverageNo product wins every dimension — these are trade-offs, not a scoreboard. Where the dataset can’t yet support hard medians, we show the observed range and the analyst’s read.
- Most agency CI products are renewable-term structures (5/10/15-year periods) rather than whole-life CI cover.
- Early CI + Major CI + Premium Waiver triple-stack (Allianz pattern) is differentiating relative to single-stage products.
- Booster/return-of-premium tail benefits are increasingly standard for premium-tier CI.
- Sharia CI products follow conventional structure with Tabarru' / Wakalah bil Ujrah overlay.
- TMLI tm-ci-guard and tm-critical-guard are publishing-gap B set; lower confidence on full-feature comparison.
Coverage caveat: Critical-illness category is structurally heterogeneous: comprehensive CI lump-sum, early-stage CI add-ons, gender/condition-specific products, and recurring-payment CI. Aggregate quantitative benchmarking across these structures is misleading; sub-category qualitative comparison is preferred. Briefs rely on qualitative comparison plus direct PDF reading. (sample: ~23 products)
Expert · full Strategic Brief
No Strategic Brief yet for this product — analysis pending.
Switch to Expert (top-right) for the full 10-section brief, benchmarks, compliance flags, and source documents.